Ying‐Jun Chang
YOU?
Author Swipe
View article: Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation
Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation Open
Chronic graft-versus-host disease (cGVHD) is a major complication of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). In our previous studies, we speculated that cGVHD might be closely related to immune-mediated encepha…
View article: Recent Advances in nccRCC Classification and Therapeutic Approaches
Recent Advances in nccRCC Classification and Therapeutic Approaches Open
Non-clear cell renal cell carcinoma (nccRCC) constitutes a biologically diverse category of renal malignancies. The 2022 WHO classification framework has significantly evolved to incorporate molecularly defined entities alongside tradition…
View article: Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia
Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia Open
IntroductionPrimary immune thrombocytopenia (ITP) is an autoimmune disease, posing a serious threat to human health as one of the most common bleeding disorders. Improving response rates and durability to current therapies remains an unmet…
View article: Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia
Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia Open
Background： Early death in high-risk acute promyelocytic leukemia (APL) is closely related to the leukocytosis at the onset of the disease. During induction, cytoreductive chemotherapy is a critical early intervention. Current internationa…
View article: Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia
Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia Open
Background With the identification of increasing molecular markers, acute myeloid leukemia (AML) patients in the adverse risk group constitute a growing proportion of the overall AML population according to the 2022 European LeukemiaNet ge…
View article: A novel Janus kinase 1 and 2 inhibitor, baricitinib, for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation
A novel Janus kinase 1 and 2 inhibitor, baricitinib, for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation Open
Introduction Allogeneic stem cell transplantation (allo-SCT) is an effective and straightforward therapy for hematology patients, and chronic graft-versus-host disease (cGVHD) is recognized as a major and important complication of HSCT. cG…
View article: Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation
Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation Open
Introduction: Liver abscess (LA), a severe and potentially life-threatening infection, is characterized by the formation of purulent material within the liver parenchyma, often resulting from bacterial, fungal, or parasitic infections. In …
View article: Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation
Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation Open
Introduction Autoimmune hemolytic anemia (AIHA) is a rare yet serious hematologic disorder, defined as hemolytic anemia characterized by the destruction of red blood cells (RBCs) mediated by autoantibodies targeting antigens on the RBC sur…
View article: Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial
Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial Open
Introduction Despite all-trans retinoic acid (ATRA) -arsenical regimens achieve high cure rates in low-risk APL, relapse persists as a key challenge. Recent studies and our prior work suggest intravenous chemotherapy during induction may r…
View article: Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation
Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation Open
Introduction Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT) without an explicit etiology, and there is no standard treatmen…
View article: Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study
Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study Open
Background: KMT2A-rearranged (KMT2A-r) leukemia represents a high-risk subtype marked by aggressive biology and high early relapse risk. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is commonly used for remission consolid…
View article: Thrombotic thrombocytopenic purpura after allogeneic hematopoietic cell transplantation: A rare but fatal complication.
Thrombotic thrombocytopenic purpura after allogeneic hematopoietic cell transplantation: A rare but fatal complication. Open
Introduction Thrombotic microangiopathy (TMA) is a common and potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The underlying mechanisms of TMA after transplantation can be diverse, but c…
Single-cell dissection of pathogenic T-cell response to tacrolimus in immune thrombocytopenia Open
IntroductionPrimary immune thrombocytopenia (ITP) is an autoimmune disease characterized by excessive platelet destruction and decreased platelet production. Although T cells are known to contribute to the pathophysiology of ITP, the detai…
A retrospective cohort study on the clinical efficacy of Shanhuang Jiangzhi tablets and Atorvastatin calcium tablets in the treatment of carotid atherosclerosis Open
This study investigated the use of Shanhuang Jiangzhi tablets combined with atorvastatin calcium for carotid atherosclerosis, offering effective options for traditional Chinese medicine in managing atherosclerosis and hyperlipidaemia.
View article: Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor
Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor Open
Background Naïve T cells are maintained in a quiescent state prior to activation. As inappropriate T‐cell activation can lead to impaired immune tolerance and autoimmune diseases, the transition from quiescence to activation must be under …
View article: A New Risk Score System for Early Warning Gastrointestinal Graft-Versus-Host Disease Based on the Immune Function of Mucosal-Associated Invariant T Cells
A New Risk Score System for Early Warning Gastrointestinal Graft-Versus-Host Disease Based on the Immune Function of Mucosal-Associated Invariant T Cells Open
Gastrointestinal acute graft-versus-host disease (GI aGVHD) remains one of the major clinical challenges following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early identification and intervention are critical to improv…
View article: Prognostic value of <scp><i>CEBPA</i> bZIP</scp> signatures in cytogenetically normal acute myeloid leukaemia
Prognostic value of <span><i>CEBPA</i> bZIP</span> signatures in cytogenetically normal acute myeloid leukaemia Open
Summary Recent studies revealed that CEBPA with basic leucine zipper (bZIP) in‐frame mutation ( CEBPA bZIP‐inf ) is the bona fide entity with a favourable prognosis in acute myeloid leukaemia. However, the mechanism by which the bZIP signa…
View article: Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation
Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation Open
It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognos…
View article: Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia
Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia Open
Acute myeloid leukemia (AML) relapse is associated with poor prognosis. While natural killer (NK) cell therapy can induce leukemia remission, infused NK cells are prone to exhaustion. Elucidating the molecular mechanisms driving NK cell ex…
View article: Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Open
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established curative treatment option for acute myeloid leukemia (AML) in second complete remission (CR2). However, whether the addition of consolidation chemo…
View article: Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know Open
Acute leukemia (AL), which includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is a hematological malignancy characterized by the uncontrolled proliferation of immature myeloid or lymphoid cells. Allogeneic stem c…
View article: Monitoring the <scp> <i>KMT2A</i> </scp> gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation
Monitoring the <span> <i>KMT2A</i> </span> gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation Open
Summary This study evaluated the kinetics of KMT2A ‐r during chemotherapy and its impact on allogeneic haematopoietic stem cell transplantation (allo‐HSCT) outcomes. KMT2A‐r was assessed post‐induction (MRD1), after the first (MRD2) and se…
View article: Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group Open
Our results suggest that IC remains the cornerstone of therapy, whereas VEN-AZA may also be used in younger patients and medically fit patients with adverse-risk AML who are receiving allo-HSCT in CR1.
View article: Characterizing the Heterogeneity of MAIT Cells in Grafts Using Single-Cell RNA Sequencing to Assist in the Precise Diagnosis of Gastrointestinal GVHD
Characterizing the Heterogeneity of MAIT Cells in Grafts Using Single-Cell RNA Sequencing to Assist in the Precise Diagnosis of Gastrointestinal GVHD Open
Granulocyte colony-stimulating factor (G-CSF) enhances acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT) by inducing T cell tolerance and altering graft cell composition. …